Macromoltek Offers Computational De Novo Antibody Design Targeting COVID-19
By HospiMedica International staff writers Posted on 10 Apr 2020 |
Illustration
Macromoltek, Inc. (Austin, TX, USA), a computational de novo drug design company that rapidly produces antibody designs, has announced computational de novo design capability to speed up the development of human monoclonal antibodies for the potential treatment of COVID-19.
Macromoltek is a pioneer in computational de novo design of antibodies, the proteins produced in an immune response by the body to fight off pathogens like bacteria and viruses. Over the last 10 years, the company has built a highly accurate computational platform, which has been successfully applied in a number of commercial and research projects. The platform generates de novo antibody designs using an automated process of structural modeling and machine learning.
Traditional in vivo methods test for the likelihood of producing an antibody that triggers the body's immune system to fight against pathogens. Also, scaling up an in silico project is faster, simpler and easier than traditional drug design programs. In silico techniques can be developed and delivered remotely, and do not require the on-site presence needed for traditional wet labs.
"As we face a global onslaught from COVID-19, computational de novo design techniques will lead the charge for rapid design iterations and faster drug development," said Monica Berrondo, CEO of Macromoltek. "The longer it takes to develop effective therapeutics, the worse the impact on society."
Related Links:
Macromoltek, Inc.
Macromoltek is a pioneer in computational de novo design of antibodies, the proteins produced in an immune response by the body to fight off pathogens like bacteria and viruses. Over the last 10 years, the company has built a highly accurate computational platform, which has been successfully applied in a number of commercial and research projects. The platform generates de novo antibody designs using an automated process of structural modeling and machine learning.
Traditional in vivo methods test for the likelihood of producing an antibody that triggers the body's immune system to fight against pathogens. Also, scaling up an in silico project is faster, simpler and easier than traditional drug design programs. In silico techniques can be developed and delivered remotely, and do not require the on-site presence needed for traditional wet labs.
"As we face a global onslaught from COVID-19, computational de novo design techniques will lead the charge for rapid design iterations and faster drug development," said Monica Berrondo, CEO of Macromoltek. "The longer it takes to develop effective therapeutics, the worse the impact on society."
Related Links:
Macromoltek, Inc.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans